Gene-modified T cell therapy
Immune checkpoint inhibitor therapy has achieving a sensational success in the treatment of patients with progressive cancers. However, the efficacy remains as 10-30% of the pa- tients in most type of cancers, suggesting that the development of new treatments for pa- tients resistant to the therapy...
Saved in:
| Published in | Nihon rinshō Vol. 75; no. 2; p. 275 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Japanese |
| Published |
Japan
01.02.2017
|
| Online Access | Get more information |
Cover
Loading…
| Summary: | Immune checkpoint inhibitor therapy has achieving a sensational success in the treatment of patients with progressive cancers. However, the efficacy remains as 10-30% of the pa- tients in most type of cancers, suggesting that the development of new treatments for pa- tients resistant to the therapy is an important challenge of the field. It is likely that the patients without the induction of tumor-specific lymphocytes in the body will not respond to immune checkpoint inhibitor. Therefore, adoptive cell therapy with gene-modified tumor- specific T cells will be one promising treatment of the patients resistant to checkpoint inhibitor therapy. This review summarizes the recent progress in the clinical development of gene- modified T cell therapy and discusses the issues that should be improved in the near future. |
|---|---|
| ISSN: | 0047-1852 |